⌕
VIR Biotechnology · VIR · Nasdaq
Tenet 54 · Mixed
Compare
$9.25−3.44%At closeTenet 54 · Mixed
$9.25−0.33 (−3.44%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

VIR Biotechnology (VIR) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is VIR's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Business WireNov 12, 2026 · 19:38 ETCOMPANY'S OWN WORDS
Vir Biotechnology Announces Pricing of Public Offering of Common Stock

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serio…

VIR −3.4% todayRead at source ↗
● Business WireNov 12, 2026 · 16:08 ETCOMPANY'S OWN WORDS
Vir Biotechnology Announces Proposed Public Offering

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serio…

VIR −3.4% todayRead at source ↗
● MarketBeatNov 10, 2026 · 09:13 ET
Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48

Vir Biotechnology NASDAQ: VIR said its combination treatment for chronic hepatitis delta met the primary and key secondary endpoints in the pivotal Phase III ECLIPSE 1 trial, with 79% of treated patients achieving undete…

VIR −3.4% todayRead at source ↗
● Seeking AlphaNov 10, 2026 · 08:15 ET
Vir Biotechnology: Fairly Valued After Phase 3 Success?

Vir Biotechnology remains a Buy after flawless Phase 3 ECLIPSE 1 results and a major new Gilead partnership. VIR's Hepatitis Delta therapy achieved 44% primary endpoint success and 79% undetectable virus rates, with a st…

VIR −3.4% todayRead at source ↗
● Seeking AlphaNov 9, 2026 · 14:10 ET
Vir Biotechnology, Inc. (VIR) Discusses ECLIPSE 1 Topline Results and Expanded SOLSTICE Data Transcript

Vir Biotechnology, Inc. ( VIR ) Discusses ECLIPSE 1 Topline Results and Expanded SOLSTICE Data November 9, 2026 8:30 AM EST Company Participants Kiki Patel - Head of Investor Relations Marianne De Backer - President, CEO…

VIR −3.4% todayRead at source ↗
● Investors Business DailyNov 9, 2026 · 13:05 ET
Vir, A Gilead Rival, Shoots To Two-Year High On Its 'Clean Win' In Hepatitis D Treatment

Vir stock catapulted to a nearly two-year high Monday on a "clean win" for its experimental hepatitis D treatment.…

VIR −3.4% todayRead at source ↗
● Zacks Investment ResearchNov 9, 2026 · 10:56 ET
Wall Street Analysts Predict a 75.59% Upside in Vir Biotechnology (VIR): Here's What You Should Know

The mean of analysts' price targets for Vir Biotechnology (VIR) points to a 75.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising…

VIR −3.4% todayRead at source ↗
● Business WireNov 8, 2026 · 16:45 ETCOMPANY'S OWN WORDS
Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced new, expanded data from the Phase 2 SOLSTICE trial evaluating monthly subcutaneous administration of elebsiran and tobevibart in adul…

VIR −3.4% todayRead at source ↗
● Business WireNov 8, 2026 · 16:15 ETCOMPANY'S OWN WORDS
Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced positive topline results from the pivotal Phase 3 ECLIPSE 1 trial evaluating monthly subcutaneous administration of elebsiran and tob…

VIR −3.4% todayRead at source ↗
● Business WireNov 5, 2026 · 10:00 ETCOMPANY'S OWN WORDS
Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD's The Liver Meeting® 2026 and Host Investor Conference Call

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the pivotal Phase 3 ECLIPSE 1 trial evaluating the combination of elebsiran and tobevibart for chro…

VIR −3.4% todayRead at source ↗
● MarketBeatNov 5, 2026 · 04:17 ET
What Vir Biotechnology (VIR) Said on Its Q3 Earnings Call

Vir Biotechnology NASDAQ: VIR expects to report the first phase 3 results for its experimental hepatitis delta treatment in the fourth quarter of 2026, with data from two additional studies due in the first quarter of 20…

VIR −3.4% todayRead at source ↗
● Seeking AlphaNov 4, 2026 · 23:14 ET
Vir Biotechnology, Inc. (VIR) Q3 2026 Earnings Call Transcript

Vir Biotechnology, Inc. (VIR) Q3 2026 Earnings Call Transcript…

VIR −3.4% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 20:46 ET
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.8. This compares to a loss of $1.17 per share a year ago.…

VIR −3.4% todayRead at source ↗
● Business WireNov 4, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the third quarter ended September 30, 2026. “We are entering an important period…

VIR −3.4% todayRead at source ↗
● Business WireNov 2, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Vir Biotechnology to Participate in the Jefferies 2026 London Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, President and Chief Executive Officer, will present at the Jefferies 2026 London Healthca…

VIR −3.4% todayRead at source ↗
● Business WireOct 28, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors

SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced the appointment of Suzanne Topalian, M.D., to its Board of Directors, effective October 27, 2026. Dr. Topalian is the Bloombe…

VIR −3.4% todayRead at source ↗
● Seeking AlphaOct 27, 2026 · 06:17 ET
Vir Biotechnology: A Big Pharma Collaboration And 2 Clinical Catalysts This Quarter

VIR's PRO-XTEN platform has attracted major pharma collaborations, validating its dual-masked T-cell engager technology for oncology and solid tumors. Near-term catalysts include ECLIPSE program readouts for hepatitis de…

VIR −3.4% todayRead at source ↗
● Defense WorldOct 22, 2026 · 02:45 ET
Critical Survey: REGENXBIO (NASDAQ:RGNX) versus Vir Biotechnology (NASDAQ:VIR)

REGENXBIO (NASDAQ: RGNX - Get Free Report) and Vir Biotechnology (NASDAQ: VIR - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on …

VIR −3.4% todayRead at source ↗
● Zacks Investment ResearchOct 15, 2026 · 15:20 ET
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?

Gilead Sciences expands its oncology pipeline through a Vir Biotechnology deal worth up to $1.74 billion in additional milestones, targeting three novel cancer therapies.…

VIR −3.4% todayRead at source ↗
● BenzingaOct 14, 2026 · 12:58 ET
Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments

Vir Biotechnology Inc. (NASDAQ:VIR) announced a major collaboration with Gilead Sciences Inc. (NASDAQ:GILD) to create three novel T-cell engagers (TCEs) aimed at treating solid tumors.…

VIR −3.4% todayRead at source ↗
● Business WireOct 14, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced a collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN® dual-masked T-cell engager (TCE) dev…

VIR −3.4% todayRead at source ↗
● Business WireOct 8, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN® dual-masked T-c…

VIR −3.4% todayRead at source ↗
● Defense WorldOct 8, 2026 · 04:15 ET
uniQure (NASDAQ:QURE) and Vir Biotechnology (NASDAQ:VIR) Critical Review

Vir Biotechnology (NASDAQ: VIR - Get Free Report) and uniQure (NASDAQ: QURE - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the stre…

VIR −3.4% todayRead at source ↗

No upcoming events in the feeds.

NVDA31−0.4%

Article counts from the last market-wide feed page, across every symbol we track and not just VIR · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.